NasdaqGS:CGONBiotechs
CG Oncology (CGON) Reports Promising Results In BOND-003 Trial
CG Oncology (CGON) recently reported promising developments from the BOND-003 trial with their investigational therapy, cretostimogene, showing significant efficacy in non-muscle invasive bladder cancer patients. Alongside this, the completion of enrollment in the PIVOT-006 study marks a strategic advancement in their clinical program. These events likely supported the company’s share price increase of 35% over the past month. Broad market moves, including record highs in the S&P 500 and...